<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
     xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:wfw="http://wellformedweb.org/CommentAPI/"
     xmlns:dc="http://purl.org/dc/elements/1.1/"
     xmlns:atom="http://www.w3.org/2005/Atom"
     xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
     xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
     xmlns:georss="http://www.georss.org/georss"
     xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#"
     xmlns:media="http://search.yahoo.com/mrss/">
    <channel>
        <title><![CDATA[Medical Licensure - Szura & Delonis, PLC]]></title>
        <atom:link href="https://www.szuradelonis.com/blog/categories/medical-licensure/feed/" rel="self" type="application/rss+xml" />
        <link>https://www.szuradelonis.com/blog/categories/medical-licensure/</link>
        <description><![CDATA[Szura & Delonis, PLC's Website]]></description>
        <lastBuildDate>Mon, 16 Nov 2026 16:49:19 GMT</lastBuildDate>
        
        <language>en-us</language>
        
            <item>
                <title><![CDATA[Selling Peptides Online? The Telehealth and FDA Issues Michigan Medical Practices Need to Navigate]]></title>
                <link>https://www.szuradelonis.com/blog/selling-peptides-online-the-telehealth-and-fda-issues-michigan-medical-practices-need-to-navigate/</link>
                <guid isPermaLink="true">https://www.szuradelonis.com/blog/selling-peptides-online-the-telehealth-and-fda-issues-michigan-medical-practices-need-to-navigate/</guid>
                <dc:creator><![CDATA[Szura & Delonis, PLC]]></dc:creator>
                <pubDate>Mon, 16 Nov 2026 16:49:18 GMT</pubDate>
                
                    <category><![CDATA[Health Law]]></category>
                
                    <category><![CDATA[Medical Licensure]]></category>
                
                    <category><![CDATA[Pharmacy Compliance]]></category>
                
                
                
                
                <description><![CDATA[<p>Peptide therapy has moved from specialty clinics to the telehealth storefront. A patient can now fill out an online questionnaire, speak with a clinician by video, and have an injectable peptide shipped to their door. For physicians, nurse practitioners, med spa owners, and telehealth entrepreneurs in Southeast Michigan, the business model is attractive. The legal&hellip;</p>
]]></description>
                <content:encoded><![CDATA[
<p class="wp-block-paragraph">Peptide therapy has moved from specialty clinics to the telehealth storefront. A patient can now fill out an online questionnaire, speak with a clinician by video, and have an injectable peptide shipped to their door. For physicians, nurse practitioners, med spa owners, and telehealth entrepreneurs in Southeast Michigan, the business model is attractive. The legal footing is far less settled.</p>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="559" src="/static/2026/11/Telehealth-peptides-1-1024x559.jpg" alt="" class="wp-image-2022" srcset="/static/2026/11/Telehealth-peptides-1-1024x559.jpg 1024w, /static/2026/11/Telehealth-peptides-1-300x164.jpg 300w, /static/2026/11/Telehealth-peptides-1-766x418.jpg 766w, /static/2026/11/Telehealth-peptides-1.jpg 1408w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /></figure>



<p class="wp-block-paragraph">The core problem is that two different bodies of law apply at once, and compliance with one does not satisfy the other. This post explains how Michigan’s telehealth rules and the FDA’s drug rules fit together, where the current enforcement focus is, and what to review before you launch or expand an online peptide offering.</p>



<p class="wp-block-paragraph"><strong>Two Sets of Rules, Not One</strong></p>



<p class="wp-block-paragraph">Michigan’s telehealth law governs <em>how</em> care may be delivered remotely: consent, the standard of care, and who may prescribe. Federal drug law, enforced by the FDA, governs <em>what</em> may be prescribed, compounded, and sold. A flawless telehealth visit does not make an unapproved or improperly compounded product lawful, and a lawful product does not excuse a deficient telehealth process. Practices that focus on compliance for only one side are the ones that end up in front of regulators.</p>



<p class="wp-block-paragraph"><strong>What Michigan’s Telehealth Law Requires</strong></p>



<p class="wp-block-paragraph">Michigan’s principal telehealth provisions appear at MCL 333.16283 <em>et seq.</em> In practice, the key requirements are these:</p>



<ul class="wp-block-list">
<li><strong>Informed consent first.</strong> A health professional may not provide a telehealth service without first obtaining the patient’s informed consent. The practice should document consent in the medical record and apply the current Public Health Code, any profession-specific administrative rules, and generally applicable law governing consent for minors.</li>



<li><strong>A real clinical evaluation.</strong> The treating professional must obtain sufficient clinical information, using technology appropriate to the patient’s condition and the service provided, to satisfy the same standard of care and scope-of-practice requirements that apply to in-person treatment, while complying with applicable federal and state privacy and security requirements. Michigan does not impose a universal in-person-visit prerequisite, but an in-person examination may be required when the applicable standard of care cannot be met remotely, and a questionnaire alone may be insufficient to support diagnosis or prescribing.</li>



<li><strong>Same standard of care.</strong> The rules treat telehealth as the practice of the profession, with the same scope-of-practice limits and standard of care as in-person care.</li>



<li><strong>Prescribing limits.</strong> Only authorized prescribers may prescribe within their professional scope and any applicable supervision or delegation requirements; controlled-substance prescribing must also comply with Michigan law, MAPS obligations, the federal Ryan Haight Act, 21 U.S.C. § 829(e), and then-current DEA telemedicine rules.</li>



<li><strong>Licensure follows patient location.</strong> A Michigan license generally does not authorize you to treat patients located in other states.</li>
</ul>



<p class="wp-block-paragraph">A violation of these telehealth provisions can lead to restrictions or conditions on a professional’s ability to provide telehealth services, in addition to other discipline available under the Public Health Code.</p>



<p class="wp-block-paragraph"><strong>Where Peptides Stand With the FDA</strong></p>



<p class="wp-block-paragraph">Most peptides sold online are not FDA-approved drugs for the uses being promoted. Eligibility to compound from a bulk drug substance depends on the applicable statutory pathway: section 503A, 21 U.S.C. § 353a(b)(1)(A), governs qualifying patient-specific compounding, while section 503B, 21 U.S.C. § 353b(a)(2)(A), separately governs registered outsourcing facilities; FDA approval of a finished drug, placement on a final bulks list, and treatment under an interim enforcement-discretion category are legally distinct.</p>



<p class="wp-block-paragraph">Recent developments have created confusion:</p>



<ul class="wp-block-list">
<li>FDA has identified significant safety risks for certain nominated peptide substances, including BPC-157.</li>



<li>The status of each nominated peptide should be checked against FDA’s current bulk-drug-substance materials as of publication, because withdrawal of a nomination or removal from an interim category does not establish FDA approval or statutory eligibility for compounding.</li>



<li>Any Pharmacy Compounding Advisory Committee recommendation are advisory and are not the same as the FDA taking legally operative action.</li>
</ul>



<p class="wp-block-paragraph">Headlines about “reclassification” and “committee approval” are being used in peptide marketing. Before a practice relies on any of them, confirm what the FDA has actually done.</p>



<p class="wp-block-paragraph"><strong>Enforcement Focuses on Telehealth Marketing</strong></p>



<p class="wp-block-paragraph">The FDA’s recent enforcement focus is not only on products but on how telehealth companies describe them. FDA warning letters and other enforcement materials have challenged marketing claims concerning compounded products, including claims that imply approval, generic status, or equivalence to an FDA-approved drug; any numerical enforcement summary should be tied to identified agency records and a stated cutoff date. The letters have targeted several recurring claims:</p>



<ul class="wp-block-list">
<li>Implying that a compounded product is the same as, or equivalent to, an FDA-approved drug.</li>



<li>Describing a compounded drug as “generic.”</li>



<li>Representing that a compounded product has been approved or evaluated by the FDA for safety and effectiveness.</li>



<li>Obscuring who actually compounded the drug by selling it under the telehealth company’s own brand.</li>
</ul>



<p class="wp-block-paragraph">The FDA also launched a webpage for telehealth companies describing common promotional pitfalls. Although those letters concerned GLP-1 products, the same misbranding theory can apply to any compounded or unapproved peptide marketed online.</p>



<p class="wp-block-paragraph"><strong>“Research Use Only” Is Not a Safe Harbor</strong></p>



<p class="wp-block-paragraph">Some online sellers label peptides “for research use only” or “not for human consumption.” FDA has issued multiple warning letters to online sellers using those labels where the surrounding promotional claims and distribution practices indicated an intended use in humans. A disclaimer does not control intended use when objective evidence, including website claims, dosing instructions, product presentation, or distribution practices, indicate that a product is intended for human use. Product pages that discuss weight loss or appetite, give dosing guidance, or sell injection supplies alongside the peptide may be relied upon by regulators.</p>



<p class="wp-block-paragraph">For a licensed professional, the lesson is direct: sourcing from a “research” vendor and prescribing or administering the product to a patient is not a workaround. It can expose both the seller and the clinician.</p>



<p class="wp-block-paragraph"><strong>Why Licensed Professionals Carry Extra Risk</strong></p>



<p class="wp-block-paragraph">A physician or nurse practitioner who serves as the prescriber or medical director for an online peptide business may face more than an FDA letter:</p>



<ul class="wp-block-list">
<li><strong>Licensing discipline.</strong> The Public Health Code authorizes professional discipline on grounds that may include negligence, incompetence, unprofessional conduct, and violations of applicable law under MCL 333.16221, with sanctions available under MCL 333.16226; the particular ground depends on the conduct and profession involved.</li>



<li><strong>Federal liability.</strong> Introducing an unapproved new drug or a misbranded drug into interstate commerce may violate federal law and may support remedies including injunction, seizure, or criminal enforcement.</li>



<li><strong>Private claims.</strong> Manufacturers of approved drugs have sued compounders, med spas, medical practices, and telehealth providers, and patients injured by a product have their own claims.</li>
</ul>



<p class="wp-block-paragraph"><strong>Practical Steps for Practices</strong></p>



<ul class="wp-block-list">
<li><strong>Verify the product’s legal status.</strong> For each peptide, confirm whether it is FDA-approved, eligible for compounding, or neither, and document how you reached that conclusion.</li>



<li><strong>Know your pharmacy.</strong> Use a properly licensed pharmacy and confirm its authority to compound the specific substance under the applicable section 503A or 503B pathway; patient-specific prescriptions are generally central to section 503A, whereas registered outsourcing facilities operate under the distinct conditions of section 503B.</li>



<li><strong>Audit your website and ads.</strong> Remove claims of equivalence, “generic” descriptions, implied FDA approval, and any language suggesting a compounded product has been FDA-evaluated. Identify the compounding pharmacy clearly.</li>



<li><strong>Build a real telehealth workflow.</strong> Obtain and document informed consent, gather sufficient clinical information through technology appropriate to the patient and service, satisfy the applicable standard of care and prescribing requirements, and maintain records required by Michigan law and profession-specific rules.</li>



<li><strong>Check licensure for every patient location.</strong> Confirm that each clinician is licensed where the patient is physically located.</li>



<li><strong>Review your ownership and contracts.</strong> Have counsel review the structure among the clinician, any management company, and the pharmacy.</li>



<li><strong>Avoid “research” shortcuts.</strong> Do not source or administer products labeled for research use only.</li>
</ul>



<p class="wp-block-paragraph"><strong>When to Talk to a Health Care Attorney</strong></p>



<p class="wp-block-paragraph">It is far cheaper to answer these questions before launch. Consider a consultation if:</p>



<ul class="wp-block-list">
<li>You are planning to start or expand an online peptide or weight-loss telehealth program.</li>



<li>You received an FDA warning letter or a state inquiry, or a pharmacy partner has questioned your marketing.</li>



<li>You are a prescriber being asked to serve as medical director for a business you did not build.</li>



<li>LARA has contacted you about a telehealth, prescribing, or advertising issue.</li>
</ul>



<p class="wp-block-paragraph"><strong>Frequently Asked Questions</strong></p>



<p class="wp-block-paragraph"><strong>Can I prescribe peptides through telehealth in Michigan?</strong> Michigan law allows licensed prescribers to prescribe through telehealth after obtaining informed consent and performing an appropriate evaluation. Whether a particular peptide may lawfully be compounded or sold is a separate federal question that must be answered first.</p>



<p class="wp-block-paragraph"><strong>Does a “research use only” label protect a seller?</strong> The FDA has said it does not, when the seller’s website shows the product is intended for human use.</p>



<p class="wp-block-paragraph"><strong>Can I describe a compounded product as the same as a brand-name drug?</strong> No. FDA warning letters have challenged unsupported claims that compounded products are the same as, equivalent to, or generic versions of FDA-approved drugs, but each marketing claim should be assessed under the applicable misbranding provisions, including 21 U.S.C. § 352, and the specific facts of the promotion.</p>



<p class="wp-block-paragraph">If you operate or advise an online peptide or telehealth practice, the attorneys at Szura & Delonis, PLC represent health care professionals and businesses across Oakland, Wayne, Macomb, and Washtenaw Counties. Call (248) 716-3600 or <a href="https://www.szuradelonis.com/contact-us/" target="_blank" rel="noopener">contact us online</a> to discuss your situation before a regulator does.</p>



<hr class="wp-block-separator has-alpha-channel-opacity" />



<p class="wp-block-paragraph"><em>This post is intended for general informational purposes and does not constitute legal advice. FDA policy on peptides and federal and state telehealth requirements may change, and each practice’s obligations depend on the product, compounding pathway, prescriber’s professional authority, patient’s location, and then-current law as of the date of service. If you have questions about a telehealth program, a product’s legal status, or a regulatory inquiry, consult a health care attorney before taking action.</em></p>
]]></content:encoded>
            </item>
        
            <item>
                <title><![CDATA[Louis Szura Selected to 2026 Michigan Super Lawyers® List]]></title>
                <link>https://www.szuradelonis.com/blog/louis-szura-selected-to-2026-michigan-super-lawyers-list/</link>
                <guid isPermaLink="true">https://www.szuradelonis.com/blog/louis-szura-selected-to-2026-michigan-super-lawyers-list/</guid>
                <dc:creator><![CDATA[Szura & Delonis, PLC]]></dc:creator>
                <pubDate>Tue, 10 Mar 2026 17:47:50 GMT</pubDate>
                
                    <category><![CDATA[Business Law]]></category>
                
                    <category><![CDATA[Health Law]]></category>
                
                    <category><![CDATA[Medical Licensure]]></category>
                
                
                
                
                    <media:thumbnail url="https://szuradelonis-com.justia.site/wp-content/uploads/sites/1370/2025/11/SL2026.png" />
                
                <description><![CDATA[<p>Szura & Delonis, PLC is pleased to announce that partner Louis Szura has been selected to the 2026 Michigan Super Lawyers® list in the area of healthcare law. Super Lawyers® is a rating service that recognizes outstanding attorneys who have attained a high degree of peer recognition and professional achievement. Selection is based on a&hellip;</p>
]]></description>
                <content:encoded><![CDATA[
<p>Szura & Delonis, PLC is pleased to announce that partner Louis Szura has been selected to the 2026 Michigan Super Lawyers® list in the area of healthcare law.</p>



<p>Super Lawyers® is a rating service that recognizes outstanding attorneys who have attained a high degree of peer recognition and professional achievement. Selection is based on a combination of independent research, peer nominations, and peer evaluations, and is limited to a small percentage of lawyers in each state.</p>



<p>Louis’s inclusion on the 2026 Michigan Super Lawyers® list reflects his ongoing commitment to representing physicians, group practices, and other healthcare providers in complex regulatory, licensure, and business disputes. Over the course of his career, he has focused on helping healthcare professionals navigate the legal and compliance challenges that come with practicing in one of the most highly regulated industries.</p>



<p>At Szura & Delonis, Louis advises and represents healthcare clients in matters involving:</p>



<ul class="wp-block-list">
<li>Medical license investigations and proceedings</li>



<li>Healthcare fraud and False Claims Act concerns</li>



<li>Stark Law and anti-kickback compliance</li>



<li>Contract and business disputes involving healthcare practices</li>
</ul>



<p>We believe this acknowledgment underscores our firm’s commitment to delivering practical, focused counsel to providers across Michigan.</p>



<p>For more information about Louis Szura’s practice or to discuss a healthcare law or licensure matter, please contact Szura & Delonis, PLC.</p>
]]></content:encoded>
            </item>
        
            <item>
                <title><![CDATA[Protect Your Michigan Pharmacy: Stay Ahead of Compliance Risks in 2026]]></title>
                <link>https://www.szuradelonis.com/blog/protect-your-michigan-pharmacy-stay-ahead-of-compliance-risks-in-2026/</link>
                <guid isPermaLink="true">https://www.szuradelonis.com/blog/protect-your-michigan-pharmacy-stay-ahead-of-compliance-risks-in-2026/</guid>
                <dc:creator><![CDATA[Szura & Delonis, PLC]]></dc:creator>
                <pubDate>Mon, 23 Feb 2026 19:26:39 GMT</pubDate>
                
                    <category><![CDATA[Health Law]]></category>
                
                    <category><![CDATA[Medical Licensure]]></category>
                
                    <category><![CDATA[Pharmacy Compliance]]></category>
                
                
                    <category><![CDATA[Health Care Law]]></category>
                
                    <category><![CDATA[Medical Licence Defense]]></category>
                
                    <category><![CDATA[Pharmacy Compliance]]></category>
                
                    <category><![CDATA[Pharmacy Law]]></category>
                
                
                
                <description><![CDATA[<p>Running a pharmacy in Michigan means navigating one of the most tightly regulated healthcare environments in the country. Between the Michigan Public Health Code, Board of Pharmacy regulations, DEA oversight, and shifting federal rules on controlled substances and telehealth prescribing, compliance isn’t just good practice—it’s essential for survival. Whether you operate an independent pharmacy or&hellip;</p>
]]></description>
                <content:encoded><![CDATA[
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="940" height="788" src="/static/2026/02/Facebook-Post-Protecting-Pharmacists-Rights.png" alt="" class="wp-image-1582" srcset="/static/2026/02/Facebook-Post-Protecting-Pharmacists-Rights.png 940w, /static/2026/02/Facebook-Post-Protecting-Pharmacists-Rights-300x251.png 300w, /static/2026/02/Facebook-Post-Protecting-Pharmacists-Rights-768x644.png 768w" sizes="auto, (max-width: 940px) 100vw, 940px" /></figure>



<p>Running a pharmacy in Michigan means navigating one of the most tightly regulated healthcare environments in the country. Between the Michigan Public Health Code, Board of Pharmacy regulations, DEA oversight, and shifting federal rules on controlled substances and telehealth prescribing, compliance isn’t just good practice—it’s essential for survival.</p>



<p>Whether you operate an independent pharmacy or manage a chain location, even a minor oversight in recordkeeping, billing, or licensing can trigger investigations, costly penalties, or even professional discipline. At <strong>Szura & Delonis PLC</strong>, we help Michigan pharmacists and pharmacy owners protect their businesses, their licenses, and their reputations.Running a pharmacy in Michigan means navigating one of the most tightly regulated healthcare environments in the country. Between the Michigan Public Health Code, Board of Pharmacy regulations, DEA oversight, and shifting federal rules on controlled substances and telehealth prescribing, compliance isn’t just good practice—it’s essential for survival.</p>



<p>Whether you operate an independent pharmacy or manage a chain location, even a minor oversight in recordkeeping, billing, or licensing can trigger investigations, costly penalties, or even professional discipline. At&nbsp;<strong>Szura & Delonis PLC</strong>, we help Michigan pharmacists and pharmacy owners protect their businesses, their licenses, and their reputations.</p>



<h2 class="wp-block-heading" id="h-the-growing-complexity-of-pharmacy-compliance"><strong>The Growing Complexity of Pharmacy Compliance</strong></h2>



<p>The last few years have brought sweeping changes to how pharmacies must operate. The Michigan Department of Licensing and Regulatory Affairs (LARA) now expects heightened accountability in controlled substance dispensing, pharmacy technician supervision, compounding standards, and credential renewals. At the same time, federal regulators and insurers are cracking down on billing irregularities and documentation errors.</p>



<p>Common risk areas for Michigan pharmacies include:</p>



<ul class="wp-block-list">
<li>Inadequate controlled substance tracking or inventory reconciliation</li>



<li>Billing or coding errors under Medicare, Medicaid, or private payers</li>



<li>Failure to properly supervise technicians or interns</li>



<li>Violations involving remote or off-site dispensing</li>



<li>Recordkeeping deficiencies during board or DEA audits</li>
</ul>



<p>Pharmacies often find themselves facing regulatory investigations, audit demands, or complaints without warning. By the time a notice arrives, the clock is already ticking—and what you say or submit in response can determine the outcome.</p>



<h2 class="wp-block-heading" id="h-how-szura-amp-delonis-helps-michigan-pharmacies"><strong>How Szura & Delonis Helps Michigan Pharmacies</strong></h2>



<p>Our attorneys represent pharmacies and pharmacists across Michigan in all stages of regulatory compliance, investigation, and defense. With decades of combined experience in healthcare law and administrative proceedings, we understand how regulators think and what actions protect your license.</p>



<p>Our services include:</p>



<ul class="wp-block-list">
<li>Proactive compliance audits and policy development</li>



<li>Defense of pharmacy license complaints before LARA and the Board of Pharmacy</li>



<li>Response strategies for DEA, auditor, or Department of Health investigations</li>



<li>Risk management advice tailored to Michigan pharmacy operations</li>



<li>Training for staff on documentation and regulatory communication</li>
</ul>



<p>We know that every pharmacy operates differently, so our guidance is designed to fit your specific operations and risk profile. When you need experienced counsel, you want a team that understands both the letter of the law and the realities of running a modern pharmacy.</p>



<h2 class="wp-block-heading" id="h-take-action-before-problems-arise"><strong>Take Action Before Problems Arise</strong></h2>



<p>Too often, pharmacies reach out only after receiving a subpoena, audit letter, or notice of violation. By then, options can be more limited. Taking proactive steps now—reviewing your policies, conducting internal audits, and shoring up documentation—is one of the most cost-effective ways to secure your business and license.</p>



<p>If your Michigan pharmacy has questions about compliance, licensing, or pending investigations, don’t wait to seek experienced legal guidance.</p>



<p><strong>Contact Szura & Delonis PLC today</strong>&nbsp;to schedule a confidential consultation. Call us to learn how we can help your pharmacy stay protected, compliant, and successful in 2026 and beyond.</p>
]]></content:encoded>
            </item>
        
            <item>
                <title><![CDATA[Michigan Medical License Defense: Responding to a LARA Administrative Complaint]]></title>
                <link>https://www.szuradelonis.com/blog/michigan-medical-license-defense-responding-to-a-lara-administrative-complaint/</link>
                <guid isPermaLink="true">https://www.szuradelonis.com/blog/michigan-medical-license-defense-responding-to-a-lara-administrative-complaint/</guid>
                <dc:creator><![CDATA[Szura & Delonis, PLC]]></dc:creator>
                <pubDate>Fri, 23 Jan 2026 19:09:52 GMT</pubDate>
                
                    <category><![CDATA[Health Law]]></category>
                
                    <category><![CDATA[Medical Licensure]]></category>
                
                
                
                
                <description><![CDATA[<p>When a Michigan doctor, pharmacist or other healthcare professional receives a call or letter from the Department of Licensing and Regulatory Affairs (LARA), everything can change immediately. As healthcare attorneys focused on Michigan medical license defense, we’ve seen firsthand how unsettling this process can be — but I’ve also helped countless physicians, nurses, and other&hellip;</p>
]]></description>
                <content:encoded><![CDATA[
<p>When a Michigan doctor, pharmacist or other healthcare professional receives a call or letter from the Department of Licensing and Regulatory Affairs (LARA), everything can change immediately. As <a href="https://www.szuradelonis.com/practice-areas/health-care-law/">healthcare attorneys</a> focused on Michigan medical license defense, we’ve seen firsthand how unsettling this process can be — but I’ve also helped countless physicians, nurses, and other licensed professionals navigate it successfully. If you’re facing a LARA administrative complaint, the most important thing to remember is that you have rights and options. Here’s how the process works and what an experienced medical license defense lawyer can do to safeguard your career</p>



<h2 class="wp-block-heading" id="h-step-1-the-lara-investigation">Step 1: The LARA Investigation</h2>



<p>The process often begins when LARA’s <a href="https://www.michigan.gov/lara/bureau-list/bpl/health">Bureau of Professional Licensing (BPL) </a>receives a complaint — sometimes from a patient, colleague, hospital, or insurance company. That report starts an investigation, during which state investigators may request records, interview witnesses or attempt to interview you directly.</p>



<p>At this early stage, mistakes are common. It may feel natural to respond directly to the investigator, but even a harmless, well-meaning or incomplete statement may be used against you later. Our first role as your legal counsel is to step in immediately — to manage communications, understand how those communications affect the complaint, and control the flow of information so that we can protect you from unnecessary exposure.</p>



<h2 class="wp-block-heading" id="h-step-2-the-administrative-complaint">Step 2: The Administrative Complaint</h2>



<p>If LARA believes the investigation uncovered a violation of the<a href="https://www.legislature.mi.gov/Laws/MCL?objectName=mcl-368-1978-15"> Michigan Public Health Code</a>, LARA or the Michigan Attorney General’s office will issue an Administrative Complaint. This is the formal document that sets out the specific allegations and Michigan Public Health Code rules that were allegedly violated.</p>



<p>From the day that complaint is served, a license holder has 30 days to file a written answer, request a compliance conference and/or demand an administrative hearing. Missing this deadline can result in serve penalties such as a default judgment leading to disciplinary action. We will carefully review the complaint’s language, examining both the factual accuracy and the legal support for each charge.  We will then discuss and prepare a strategic response that protects your rights and seeks the best path forward.</p>



<h2 class="wp-block-heading" id="h-step-3-the-compliance-conference">Step 3: The Compliance Conference</h2>



<p>Once the answer is filed, we may decide to request a compliance conference — essentially a settlement discussion that happens before the case proceeds to a full hearing. This is an opportunity to provide your side of the story. A representative from LARA or the Attorney General’s office, and sometimes a member (conferee) of the licensing board may attend. These are typically done over the phone or video conference.</p>



<p>This meeting is a crucial opportunity to present mitigating evidence, clarify misunderstandings, and explore resolution options. With thorough preparation, we have been able to negotiate outcomes such as dismissal, reduced sanctions, or agreements that allow my clients to continue practicing under reasonable conditions.</p>



<h2 class="wp-block-heading" id="h-step-4-administrative-hearing">Step 4: Administrative Hearing</h2>



<p>If the case isn’t resolved through negotiation, it moves to a<a href="https://www.michigan.gov/lara/bureau-list/moahr/licensing/health"> formal administrative hearing before an Administrative Law Judge (ALJ)</a>. This stage is very similar to a court trial — witnesses testify, evidence is introduced, and both sides make legal arguments during the hearing and through briefs.</p>



<p>In the courtroom, we present a <a href="https://www.szuradelonis.com/practice-areas/litigation/">robust defense</a> — using expert testimony, medical records, and procedural arguments to show that there was no violation of the Michigan Public Health Code, professional standards were satisfied or that the alleged violation doesn’t warrant discipline. The ALJ then issues a Proposal for Decision (PFD), we provide a response the PFD and then it goes to the appropriate licensing board to either approve or deny the proposal.</p>



<h2 class="wp-block-heading" id="h-step-5-appeals-and-reinstatement">Step 5: Appeals and Reinstatement</h2>



<p>If discipline is imposed, you still have options. You can appeal the board’s decision to the Michigan Court of Appeals, or, if necessary, petition for reinstatement of your license after fulfilling the required conditions. We work with providers throughout this process to demonstrate remediation, continuing education, and compliance with prior orders — steps that help rebuild professional standing.</p>



<h2 class="wp-block-heading" id="h-protecting-your-license-and-your-future">Protecting Your License and Your Future</h2>



<p>Facing a LARA license investigation or Administrative Complaint can be an intimidating experience, but early and well-informed action makes all the difference. As attorneys who focus on Michigan medical license defense, our goal is to ensure that one complaint doesn’t erase years of hard work and dedication.</p>



<p>If you’ve received a notice from LARA or the Board of Medicine, don’t wait to see what happens next. Contact an experienced healthcare defense attorney to preserve your rights and take control of the process before it escalates.</p>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="738" src="/static/2026/01/operation-1807543_1280-1024x738.jpg" alt="" class="wp-image-1256" srcset="/static/2026/01/operation-1807543_1280-1024x738.jpg 1024w, /static/2026/01/operation-1807543_1280-300x216.jpg 300w, /static/2026/01/operation-1807543_1280-768x554.jpg 768w, /static/2026/01/operation-1807543_1280.jpg 1280w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /></figure>
]]></content:encoded>
            </item>
        
            <item>
                <title><![CDATA[Louis Szura Named as State Bar Health Care Law Section Chair]]></title>
                <link>https://www.szuradelonis.com/blog/louis-szura-named-as-state-bar-health-care-law-section-chair/</link>
                <guid isPermaLink="true">https://www.szuradelonis.com/blog/louis-szura-named-as-state-bar-health-care-law-section-chair/</guid>
                <dc:creator><![CDATA[Szura & Delonis, PLC]]></dc:creator>
                <pubDate>Fri, 28 Sep 2018 02:32:00 GMT</pubDate>
                
                    <category><![CDATA[Business Law]]></category>
                
                    <category><![CDATA[Health Law]]></category>
                
                    <category><![CDATA[Medical Licensure]]></category>
                
                    <category><![CDATA[Medicare and Medicaid Fraud]]></category>
                
                    <category><![CDATA[Qui Tam]]></category>
                
                
                
                
                <description><![CDATA[<p>The State Bar of Michigan Health Care Law Section (HCLS) has named health care lawyer Louis C. Szura as chair for a one-year term (2018-19). Szura, a founding partner of Southfield law firm Szura & Delonis, P.L.C., was selected during the HCLS Annual Meeting on September 20th. The Health Care Law Section is one of&hellip;</p>
]]></description>
                <content:encoded><![CDATA[
<p>The State Bar of Michigan Health Care Law Section (HCLS) has named health care lawyer <a href="/lawyers/louis-szura/">Louis C. Szura</a> as chair for a one-year term (2018-19).</p>



<p>Szura, a founding partner of Southfield law firm Szura & Delonis, P.L.C., was selected during the HCLS Annual Meeting on September 20th.</p>



<p>The Health Care Law Section is one of the largest sections of the State Bar of Michigan with approximately 1,000 members. The HCLS’s numerous committees and programs provide valuable educational resources for its members around the state. Those resources include webinars and publications on emerging issues in health care law, as well in-person programs at its Annual Meeting and the annual Health Law Institute, which it co-sponsors with the Institute of Continuing Legal Education. In addition, the HCLS seeks to “serve the health care community and advocate on behalf of its interests concerning state and federal legislation and public policy which affect the practice of health care law and related issues.”</p>



<p>Szura’s previous experience with the Health Care Law Section includes service as Chair of its Publications Committee, service as Chair-Elect and as an active Council Member. Szura has also presented on numerous health law topics at HCLS events. He is also an active member of the Medical/Legal Committee of the Oakland County Bar Association.</p>



<p>Szura is a 2003 graduate of Cornell Law School, with a concentration in Business Law and Regulation. He received his undergraduate degree from the University of Michigan, He has been repeatedly selected as a Michigan Super Lawyer <em>Rising Star,</em> among other distinctions.</p>



<p>Szura represents and counsels health care clients on many aspects of their business, including complex health care regulations, such as the Stark Law, the Anti-Kickback Statute, and HIPAA. He also advises on licensing issues, telemedicine, medical staff and peer review matters, and employment matters, <a href="/practice-areas/health-care-law/">among other areas</a>. In addition, Szura has represented health care clients in a wide variety of matters in state and federal courts and in administrative hearings.</p>



<p>Szura & Delonis, P.L.C. is a firm of Michigan business lawyers who provide legal counsel for small and medium-sized businesses with a particular focus on health care law, real estate and labor and employment law.</p>
]]></content:encoded>
            </item>
        
    </channel>
</rss>